Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone augmentation and HPA axis dysregulation in PTSD
NL-OMON59176Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydrocortisone in post-traumatic stress disorder (PTSD) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Early life adversity, HPA axis functioning and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
hydrocortisone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON59176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59176.